vivax-like) in C57BL/6 mice [6,7,8]

vivax-like) in C57BL/6 mice [6,7,8]. poly(I:C) adjuvant, a TLR3 agonist. In C57BL/6, high-antibody titers Rabbit polyclonal to LRP12 were induced against PvAMA-1 and the three PvCSP variants (VK210, VK247, andP. vivax-like). Meanwhile, mixing PvAMA-1 with PvCSP-AllFLhad no impact on total IgG antibody titers, which were long-lasting. Moreover, antibodies from immunized mice acknowledged VK210 sporozoites and blood-stage parasites by immunofluorescence assay. However, in the BALB/c model, the antibody response against PvCSP-AllFLwas relatively low. PvAMA-1-specific CD3+CD4+and CD3+CD8+T-cell responses were observed in C57BL/6 mice, and the cellular response was impaired by PvCSP-AllFLcombination. More relevant, the multistage vaccine formulation provided partial protection in mice challenged with a transgenicPlasmodium bergheisporozoite expressing the homologous PvCSP protein. Keywords:malaria vaccine,Plasmodium vivax, circumsporozoite protein, apical membrane antigen 1 == 1. Introduction == Globally, there were an estimated 228 million malaria cases and 405,000 malaria deaths in 2018 according to the World Health Business (WHO) [1]. Vaccines have been responsible for the control, prevention, and eradication of many infectious diseases. However, the development of vaccines targeting parasites, such as those targetingPlasmodiumprotozoans, the causative agent of malaria, is very complex [2]. Clinical trials have focused almost entirely onPlasmodium falciparum, and the most advanced malaria vaccine candidate is usually RTS,S based on the circumsporozoite protein (CSP), now named Mosquirix. This vaccine has been evaluated in Micafungin Sodium Micafungin Sodium a large Phase 3 trial [3] and was recently (April Micafungin Sodium 2019) recommended by WHO for large-scale pilot implementations in areas of moderate-to-high malaria transmission in Africa [4]. By contrast, clinical trials withP. vivaxhave been neglected, with only two studies reported (reviewed in [5]). Considering the promising RTS,S results [4], our group [6,7,8] as well as others (reviewed in [9]) have invested in the CSP as a target forP. vivaxvaccines. However, keeping in mind the highly complex life cycle and geneticPlasmodiumvariability, it has been hypothesized that a multiantigen and multistage formulation would be more effective [10]. In this context, additional target antigens, includingP. falciparumapical membrane antigen 1 (PfAMA-1), have been tested in clinical studies combined with PfCSP [11,12,13,14]. P. vivaxCSP vaccine has also been combined into multivalent formulations or chimeric synthetic molecules. Peptides based on the regions N-terminal, central repeats, Micafungin Sodium and C-terminal of PvCSP were immunogenic in individual administrations of BALB/c mice [15],Aotusmonkeys [16], and healthy human volunteers [17]. The most advanced recombinant protein formulation forP. vivax, VMP001, merges in central region variant epitopes VK210 and VK247 and was confirmed immunogenic in mice [18,19,20,21],Rhesusmonkeys [20,22], and human naive volunteers [23]. However, these vaccines did not consider the three allelic variants ofP. vivaxCSP Micafungin Sodium (VK210, VK247, andP. vivax-like) that differ in terms of the amino acid sequence of the central protein region, which has B-cell epitopes [24,25,26]. Our group exhibited high immunogenicity with constructs fusing all three PvCSP variants (VK210, VK247, andP. vivax-like) in C57BL/6 mice [6,7,8]. These recombinant multivariant chimeric recombinant proteins were expressed inPichia pastorisyeast and comprised (i) the conserved region I (RI), which is usually reported to be a target for protective antibodies [27,28], followed by an immunodominant central repeat domain name representing the three variant repeats in tandem and the C-terminal domain name (PvCSP-AllCT) and (ii) a second recombinant protein, named PvCSP-AllFL, made up of the complete N-terminal domain name, including RI region, the central repeat domain name, and the C-terminal domain name. More relevant, both constructs formulated in the presence of the TLR3 agonist poly(I:C) conferred partial protection in models of murine malaria against Pb/Pv sporozoite (i.v.) challenge [8], though only PvCSP-AllCTefficacy was tested against Pb/Pv sporozoite (s.c.) challenge [7]. Previous studies with PfCSP have demonstrated that this antibody response to the N-terminal is usually associated with protection [29,30]. One of the most studied and well-characterizedP. falciparumblood-stage antigens for the purpose of composing a vaccine against malaria is usually AMA-1, with different formulations being assessed and tested in malaria-endemic areas in Africa [31,32,33,34]. On the other hand, little is known about the immune response induced by AMA-1 ofP. vivax. Our group has shown that recombinant constructions of PvAMA-1 are recognized by antibodies induced by natural contamination [35,36,37,38,39] and experimental immunizations [38,39,40]. The recombinant protein PvAMA-1 produced inPichia pastorisin the presence of the adjuvant QuilA (saponin isolated from the bark of theQuillaja saponariatree) inhibited the reticulocyte invasion of four differentP. vivaxThailand isolates [39]. These promising results justified its inclusion in this work to obtain a multistage vaccine formulation. This work explains the immunogenicity analysis of vaccine formulations.